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Abstract    
Noninvasive continuous cardiac output monitoring may have wide clinical applications in 
anesthesiology, emergency care and cardiology. It can improve outcomes, establish 
diagnosis, guide therapy and help risk stratification. The present article describes the theory 
behind the two noninvasive continuous monitoring methods for cardiac output assessment 
such as bioimpedance and bioreactance. The review discusses the advantages and 
disadvantages of these methods and highlights the recent method comparison studies. The use 
of bioimpedance and bioreactance to estimate cardiac output under haemodynamic challenges 
is also discussed. In particular, the article focuses on performance of the two methods in the 
assessment of fluid responsiveness using passive leg raising test and cardiac output response 
to exercise stress testing.     
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Introduction 
Cardiac output is a fundamental physiological measure used for diagnosis and guiding 
therapy in many clinical conditions. Monitoring of cardiac output has wide clinical 
application in anesthesiology, emergency care and cardiology.(1) Measurement of cardiac 
output is essential in critically ill, injured and unstable patients as it provides an indication of 
systemic oxygen delivery and global tissue perfusion.(2) Cardiac output monitoring during 
surgery is associated with reduced length of hospital stay and postoperative complications.(3-
5) Measurement of cardiac output under pharmacological and physiological stimulations 
defines overall function and performance of the heart and is an excellent predictor of 
prognosis in heart failure.(6-8) 
The first method for estimation of cardiac output was described in 1870 by Adolf Fick.(9) 
This method was the reference standard by which all other methods of determining cardiac 
output were evaluated until the introduction of the pulmonary artery catheter (PAC) in the 
1970s.(10) Cardiac output measurement with a PAC using the bolus thermodilution method 
has become the gold standard and reference method  used to compare novel technologies.(11, 
12) These methods are however invasive, expensive, require specialist expertise, and are 
associated with inherent risks and complications such as catheter-related infections, 
arrhythmias and bleeding.(13) These limitations preclude the use of invasive cardiac output 
monitoring in large number of patients limiting the application of this useful diagnostic and 
prognostic marker. 
The development of minimally invasive and non-invasive, sensitive, operator-independent 
and cost-effective techniques for cardiac output monitoring has been the focus of attention for 
several decades.(2) Minimally invasive methods frequently used and described are trans-
oesophageal Doppler, transpulmonary thermodilution, pulse counter and pulse power 
analysis, and non-invasive techniques such as CO2 and inert gas rebreathing, transthoracic 
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Doppler, thoracic bioimpedance cardiography, electrical velocimetry (modified 
bioimpedance) and bioreactance.(2, 12, 14, 15) The aim of the present review is three fold: 1) 
to describe the theory behind bioimpedance, electrical velocimetry, and bioreactance as 
methods for noninvasive continuous cardiac output monitoring; 2) to discuss the advantages 
and disadvantages of these methods and review the recent method comparison studies; and 3) 
to introduce the reader to modern uses of these devices (e.g. fluid responsiveness / passive leg 
raising, physiological stress). 
 
Bioimpedance method for measuring cardiac output  
 
Thoracic bioimpedance cardiography for measuring stroke volume, cardiac output and other 
cardiovascular variables was first described by Kubicek and associates in 1960s.(16) Its 
initial testing and application was performed in aerospace programs when central 
haemodynamic measurements and cardiac function were evaluated in astronauts.(17) The 
basis for its use was later pioneered by Lababidi and colleagues in 1970,(18) with significant 
software refinements and technical improvements over the following decades based on 
animal and human research. In the 1980s, Sramek et al(19) developed a less cumbersome 
impedance cardiography device with a new stroke volume equation that substituted the 
cylindrical model of the chest used by Kubicek et al(16) with that of a truncated cone. In 
1986, Bernstein(20) modified the equation of Sramek et al(19) by introducing into the 
formulae the actual in addition to ideal weight, which accounting for deviations from ideal 
body weight. The purpose was to determine more accurately the volume of the thorax.(4) 
The technique finally became popularized in 1990s when it use in clinical settings was 
evaluated by several multicentre studies reporting improvement in determination of left 
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ventricular ejection time, change in impedance with systole, and other markers of systole and 
diastole providing greater accuracy of non-invasive hemodynamic data.(21, 22) 
The underlying theory behind the bioimpedance cardiography is that thorax is considered as a 
cylinder perfused with fluid (blood) which has a specific resistivity. The technique is based 
on the measurements of impedance (or resistance) to transmission of a small electrical current 
throughout the body (wholebody bioimpedance) or chest area (thoracic bioimpedance). 
Bioimpedance is therefore the electrical resistance to a high-frequency low-amplitude current 
(e.g. 1.4-1.8 mA at 30-75 kHz,) transmitted from electrodes placed on the upper and lower 
thorax.(23) Conduits of low impedance (lowest resistance, equals high conductance) are 
blood and plasma (150 and 63 ohm/cm). Resistance of electrical current is higher (lower 
conductance) for cardiac muscle, lungs - reflecting air, and fat (750, 1275, and 2500 
ohm/cm).(23) When alternating low-level electrical current is applied to the whole body or 
thoracic area, the primary distribution is to the blood and extracellular fluid. Changes in the 
body’s resistance to electrical current flow over time (in milliseconds) are associated with 
dynamic changes in the blood and plasma.(24) As the aortic valve opens and blood is ejected 
rapidly into the aorta and the arterial branches, impedance to electrical current flow is 
decreased. During diastole, impedance to electrical flow returns to baseline. Therefore, the 
changes in impedance that are noted by a thoracic bioimpedance cardiography device reflect 
an increase in aortic pressure during systole, whereas changes in whole-body impedance 
reflect a proportional increase in the measurable conductance of the whole body during 
systole.(23, 24) 
Thoracic bioimpedance systems use electrodes applied at the base of the neck (thoracic inlet) 
and the costal margins (thoracic outlet), while the whole body systems use electrodes 
attached to limb extremities.(24) Standard thoracic bioimpedance cardiography systems apply 
a high-frequency electric current of known amplitude and frequency across the thorax and 
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measure changes in voltage (amplitude of the returning signal compared with the injected 
signal). The ratio between voltage and current amplitudes is a measure of transthoracic direct 
current resistance which is known as impedance [Zo], and this varies to the proportion of the 
amount of fluid to thorax. The instantaneous rate of the change of Zo related to instantaneous 
blood flow in the aorta. Therefore, the stroke volume is proportional to the product of 
maximal rate of the change in Zo (dZo/dtmax) and ventricular ejection time (VET).(2, 23)  
 
Validation studies of bioimpedance cardiography 
 
Several investigations found that bioimpedance compared favourably with thermodilution 
method in different settings including cardiac catheterization, surgical and emergency 
patients.(22, 25, 26) Van De Water and associates(27) evaluated thoracic bioimpedance 
against thermodilution method in 53 post cardiac surgery patients. They concluded that 
bioimpedance is less variable and more reproducible than is thermodilution.(27) Koobi et 
al(28) suggested bioimpedance is a useful non-invasive method for assessment of 
extracellular volume changes induced by coronary artery bypass grafting operations. Spiess 
and colleagues(29) used bioimpedance intraoperatively for patients undergoing coronary 
artery bypass graft surgery and found that the technique initially compared well with 
thermodilution, but, immediately postoperatively, the limits of agreement were wide. Of note, 
good correlation between two methods was also seen during opening of the chest. Similarly, 
Spinale et al.(30) reported good correlation between bioimpedance and thermodilution in 
patients following CABG but poor correlation in patients who developed severe tachycardia 
and frequent arrhythmias. Most recently, Lorne and associates (31) evaluated impedance 
cardiography in 32 subjects undergoing surgery with general anaesthesia. Their results 
demonstrated a high coefficient of correlation with oesophageal Doppler in addition to good 
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trending ability and acceptable limits of agreement. The authors conclude that impedance 
cardiography is a reliable method for non-invasive monitoring of cardiac output.(31) 
In contrast with previous investigations, a meta-analysis which included 154 studies reported 
a poor agreement between cardiac output measurements obtained by thoracic cardiac 
impedance and a reference method.(32) The authors suggested that the overall coefficient of 
correlation value of 0.67 indicates that impedance cardiography might be useful for trend 
analysis of different groups of patients. However, for diagnostic interpretation, the coefficient 
of correlation of 0.53 might not meet the required accuracy and therefore great care should be 
taken when thoracic impedance cardiography is applied to the cardiac patient.(32) 
Additionally, Critchley and Critchley (11) reviewed 23 studies comparing impedance 
cardiography with thermodilution. In an unweighted pooling of the data from these studies, 
they found a mean percentage error of 37%. They went on to suggest a narrower limit of 30% 
as acceptable, which they derived from the theoretical scatter expected in agreement between 
two methods whose agreement is each ±20% in relation to the true value. In this case, 
agreement between the two methods was 28.3%, which they rounded up to 30% for 
simplicity. Their argument assumed that the precision of thermodilution as the reference 
method was no worse than ±20% in relation to the real cardiac output. This they justified 
with reference to a review by Stetz et al.(33) which examined the accuracy and 
reproducibility of measurement of cardiac output by thermodilution, and a study by 
Mackenzie et al.(34) which compared three different devices for thermodilution 
measurement. 
More recently, Peyton and Chong (35) performed a meta-analysis and reviewed published 
data since 2000 on four different minimally invasive methods, one being transthoracic 
impedance cardiography, adapted for use during surgery and critical care. They examined the 
agreement in adult patients between bolus thermodilution and each method. A meta-analysis 
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was done using studies in which the first measurement point for each patient could be 
identified, to obtain a pooled mean bias, precision, and percentage error weighted according 
to the number of measurements in each study. They identified 13 studies in total using 
bioimpedance with 435 measurements and reported mean weighted bias, precision, and 
percentage error of -0.10 l/min, 1.14 l/min, 42.9%. The authors concluded that none of the 
four methods including bioimpedance has achieved agreement with bolus thermodilution 
which meets the expected 30% limits.(35)   
 
Limitations of bioimpedance cardiography and new attempts to improve the method 
 
Earlier studies reported unacceptable levels of agreement between bioimpedance and 
thermodilution.(32, 36, 37) Strong negative correlation was also reported between the 
accuracy of bioimpedance and increased fluid accumulation within the thorax with report of 
systematic underestimation of cardiac output by bioimpedance.(38) It was believed that 
devices of new generation, using novel computer technology and improved algorithms will 
improve accuracy of cardiac output determination by bioimpedance.(2, 29) However, poor 
correlation and agreement between bioimpedance and the reference method was reported in 
the setting of cardiac catheterization laboratory, heart failure, intensive care unit and in 
patients with increase lung water.(37-39)   
The major limitations in bioimpedance cardiography have been identified and include 
difficulties providing accurate cardiac output estimation in the following situations: changes 
in tissue fluid volume, respiration-induced changes in the volume of pulmonary and venous 
blood that “noise” must be filtered out from desired changes in volumetric blood flow of the 
aorta, changes in electrode contact and positioning, arrhythmias as ventricular ejection time is 
determined using the interval between QRS complexes, acute changes in tissue water, for 
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example, pulmonary or chest wall oedema or pleural effusion, noise from electrocautery, 
mechanical ventilation and surgical manipulation, changes in myocardial contractility, for 
example from anaesthetic drugs or ischemia, body motion, patients body size, and other 
physical factors that impact on electric conductivity between the electrodes and the skin (e.g. 
temperature and humidity).(2, 40, 41) 
 
Electrical velocimetry 
 
In an attempt to overcome the limitations associated with bioimpedance, investigators 
searched for way to improve existing bioimpedance technique. Recently, electrical 
velocimetry was introduced as a new bioimpedance method with the new algorithm for 
processing the impedance signal.(42) The electrical velocimetry, also known as cardiometry, 
uses the second derivate (d2Z/dt2) rather than the slope (dZ/dt[max]) of the impedance wave 
to measure aortic blood flow. Two main differences between bioimpedance and electrical 
velocimtry are defined. Firstly, the volume of the electricity participating tissue (VEPT) was 
a homogenously blood filled cylinder or truncated cone in bioimpedance. In the electrical 
velocimetry, using the new algorithm, only the intrathoracic blood volume compartment is 
the VEPT. Second difference is based on the conceptualization of what the Newtonian 
hemodynamic equivalent dZ/dtmax represents the electrical domain.(43) In the older method, 
dZ/drmax represents the ohmic equivalent of the peak flow in the ascending aorta, whereas in 
the electrical velocimetry equation dZ/dtmax represents the ohmic equivalent of the peak 
aortic blood acceleration.(44)The method has been validated on several occasions in both 
adults and children. Data from adults suggest it may be better than classical bioimpedance 
with limits of agreement at approximately the ± 30% acceptance mark. (12)  In children, it 
seems less accurate and there are no published data on trending abilities of electrical 
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velocimetry method.(12) The one study reported that in adult patients electrical velocimetry 
overestimated cardiac output to thermodilution with 17% at rest and 34% during 
exercise.(45) 
In summary, the accuracy and reliability of the majority of thoracic bioimpedance devices 
have been evaluated with inconclusive and conflicting results, which may lead to 
inappropriate clinical decision and interventions.                      
 
Bioreactance method for measuring cardiac output  
 
Due to the limitations associated with bioimpedance devices, newer methods of processing 
the impedance signal have been developed. It was suggested that in addition to changing 
resistance to blood flow (Zo), changes in intrathoracic volume also produce changes in 
electrical capacitive and inductive properties that results in phase shifts of the received signal 
relative to the applied signal.(46) Techniques for detecting relative phase shifts are inherently 
more robust and less susceptible to noise (e.g. the comparison between AM and FM radio).  
The new method, named bioreactance, accurately measures phase shift of an oscillating 
current in voltage that occur when current traverses the thoracic cavity, as opposed to 
traditional bioimpedance method, which only relies on measured changes in signal 
amplitude.(46) According to bioreactance the human thorax can be considered as an electric 
circuit with resistor (R) and a capacitor (C). Taken together R and C generate the thoracic 
impedance (Zo).(2) The values R and C determine the 2 components of impedance: 
amplitude (a) – the magnitude of the impedance measured in ohms; and phase (phi) – the 
direction of the impedance measured in degrees. The pulsatile ejection of blood from the 
heart modifies the value of amplitude and the phase of R and the value of C, leading to 
instantaneous changes in the amplitude and the phase of Zo. Phase shifts can occur only 
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because of pulsatile flow.(2, 46) The overwhelming majority of thoracic pulsatility stems 
from the aorta. Therefore, the bioreactance signal is strongly correlated with aortic flow. 
Furthermore, because the underlying level of thoracic fluid is relatively static, neither the 
underlying level of thoracic fluids nor their changes induce any phase shifts and do not 
contribute to the bioreactance signal. The bioreactance monitor contains a highly sensitive 
phase detector that continuously captures thoracic phase shift, which together results in the 
bioreactance signal.(2, 46)  
The bioreactance device is comprised of a high-frequency (75kHz) sine wave generator and 
four dual-electrode “stickers” that are used to establish electrical contact with the body. 
Within each sticker, one electrode is used by the high-frequency current generator to inject 
the high-frequency sine wave into the body, while the other electrode is used by the voltage 
input amplifier. Two stickers are placed on the right side, and two stickers are placed on the 
left side of the thorax. The stickers on the same side of the body are paired, so that the 
currents are passed between the outer electrodes of the pair and voltages are recorded from 
between the inner electrodes. A non-invasive cardiac output measurement signal is thus 
determined separately from each side of the body, and the final cardiac output measurement 
signal is obtained by averaging these two signals.(46) 
The system’s signal processing unit detects the relative phase shift (Δφ) of the input signal 
(determined by the receiving electrodes) relative to injected signal. The peak rate of change 
of φ (dφ/dtmax) is proportional to the peak aortic flow. The stroke volume (SV) is calculated 
from the following formula: SV = C x VET x dφ/dtmax, where C is a constant of 
proportionality, VET is ventricular ejection time determined by bioreactance and 
electrocardiographic signals. Specifically, the peak of the QRS complex of the ECG is used 
as the timing mark of the start of each beat. VET is then calculated as the time interval 
between the start of ejection, defined by the first zero crossing of dφ/dt signal, and the end of 
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ejection, defined by the second zero crossing of dφ/dt signal.(46) Unlike bioimpedance, 
bioreactance-based cardiac output measurements do not use static impedance (Zo) and do not 
depend on the distance between the electrodes for the calculations of SV, both factors that 
reduce the reliability of the results.(46)  The phase shift between the injected current and 
output signal received from the thorax is due to changes in blood volume in the aorta.   
          
Validation studies of bioreactance  
 
Several validation studies of bioreactance method have been conducted over the previous 
years. In initial evaluation, Keren and associates (46) reported strong correlation between 
bioreactance cardiac output and reference method (r=0.84-0.90) in preclinical and clinical 
setting. Squara et al (47) compared the bioreactance method with thermodilution in 110 
patients after cardiac surgery. The mean difference between the two methods was 0.16 l/min 
and limits of agreement were ±1.04 l/min with relative error of 9%. The precision of the 
bioreactance method was better than that of thermodilution as demonstrated with the ability 
to track changes in cardiac output accurately. In a multicentre evaluation study, involving 5 
centres  and 111 patients from cardiac catheterization laboratory, cardiac care units and 
intensive care units, Raval and colleagues (48) reported a bias of -0.09 l/min and limits of 
agreement of ±2.4 l/min between bioreactance and thermodilution with coefficient of 
correlation being >0.70 between the two methods. The authors concluded that bioreactance 
method has acceptable accuracy and challenging clinical environments. The bioreactance was 
also validated against thermodilution and Fick methods at baseline and after adenosine 
vasodilator challenge in patients with pulmonary hypertension undergoing right heart 
catheterization.(49) Results revealed that that bioreactance was more precise than 
thermodilution (3.6±1.7% vs. 9.9±5.7%, p<0.001). Bland Altman analysis revealed a mean 
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bias and limits of agreement of -0.37±2.6 l/min and 0.21±2.3 l/min, respectively. The 
adenosine challenge resulted in a similar mean increase in CO with each method. Other 
studies also demonstrated that cardiac output determined by bioreactance is comparable to 
that of minimally invasive methods including arterial pulse wave analysis and pulse wave 
counter based methods. (50, 51)  
On the other note, two recent studies questioned the accuracy of the bioreactance method. 
Kober and colleagues (52) tested hypothesis that bioreactance can accurately and precisely 
assessed cardiac index and its trending ability when compared with transpulmonary 
thermodilution during cytoreductive surgery in ovarian carcinoma in 15 patients. Results 
demonstrated concordance correlation coefficient for repeated measures correlating 
bioreactance and thermodilution was 0.32, bias was 0.26 l/min with limits of agreement of 
1.39 and 1.92 l/min with percentage error of 50.7%. The authors suggested that bioreactance 
showed acceptable accuracy and trending ability but poor precision and concluded that 
cardiac index measurement can not be solely based on bioreactance in patients undergoing 
cytoreductive surgery in ovarian carcinoma. Kupersztych-Hagege et al (53) evaluated the 
ability of a bioreactance method to estimate cardiac index and to track relative changes 
induced by volume expansion in 48 critically ill patients. Between bioreactance and 
thermodilution methods, the authors reported the bias of 0.9 l/min and limits of agreement of 
2.2 and 4.1 l/min, with percentage error of 82% and non-significant correlation between the 
two methods. The authors concluded that bioreactance can not accurately estimate the cardiac 
output in critically ill patients. However, several methodological limitations of this study 
have been identified and presented in an editorial by Denman and colleagues (54) suggesting 
that there is a lack of adequate data presented to support the authors’ conclusions.   
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Limitations of bioreactance 
 
Like several other noninvasive methods, bioreactance cardiac output measurement is based 
on the assumption that the area under the flow pulse is proportional to the product of peak 
flow and ventricular ejection time. However, there may be situations, especially during 
periods of low flow, in which this assumption may not be valid and readings may have 
decreased accuracy. (46)  
  
Direct comparison studies between bioimpedance and bioreactance 
 
Bioimpedance and bioreactance are noninvasive and continuous cardiac output monitoring 
methods with potential great clinical implications. Both are based on analysis of impedance 
signal but bioreactance has been suggested as a new promising method developed as a 
refinement of bioimpedance.(2, 40) Limited number of studies made direct comparison 
between bioimpedance and bioreactance methods for estimating cardiac output. Within a 
large multicentre evaluation of bioreactance, Raval and colleagues (48) performed a sub-
study comparing bioreactance with continuous cardiac output thermodilution and 
bioimpedance. In a subset of 7 a typical, awake, cardiac care unit patients cardiac output was 
continuously recorded over an approximately 200 minutes. While thermodilution and 
bioreactance generally tracked each other (with changes appearing first in bioreactance), 
bioimpedance systematically underestimated cardiac output for long periods of time and also 
showed higher degree of variability than bioreactance and thermodilution methods. Cardiac 
output averaged 5.4±2.1 l/min by thermodilution, 5.5±1.4 l/min by bioreactance and 2.7±0.8 
l/min by bioimpedance. In a comparison study design, Jakovljevic and colleagues (55) 
reported bioimpedance and bioreactance cardiac output estimates at rest and during different 
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exercise intensity in healthy adults. Results suggested non-significant difference between the 
two methods at rest but at peak exercise bioimpedance underestimated cardiac output by 3.2 
and 2.6 l/min compared to bioreactance and theoretically calculated cardiac output based on 
measured oxygen consumption. Due to wide limits of agreement between bioimpedance and 
bioreactance (-2.98 to 5.98 l/min) the authors concluded that the two methods can not be used 
interchangeable further suggesting that bioreactance cardiac outputs are similar to those 
estimated from measured oxygen consumption.  
Based on these direct comparison studies it appears that bioreactance method provides 
cardiac output estimates that closely reflect those obtained by thermodilution whereas 
bioimpedance systematically underestimates cardiac output. Similarly bioimpedance appears 
to underestimate cardiac output for a given physiological demand and under exercise stress 
testing when compared with bioreactance. 
 
Modern use of bioimpedance and bioreactance  
 
Evaluating cardiac output under pharmacological and physiological stimulation has been used 
to improve outcomes, establish diagnosis, guide therapy and help risk stratification in 
different clinical settings. Non-invasive cardiac output monitoring can play a crucial role in 
the assessment of volume responsiveness in intensive care unit, that is patients respond to 
fluid administration by increased cardiac output. (56) In clinical cardiology, haemodynamic 
response to exercise can help explain of the mechanisms of exercise intolerance in different 
degrees of heart failure as well as to improve risk stratification and predict survival.(57, 58) 
This section describes the use of bioreactance and bioimpedance to evaluate volume 
responsiveness and hemodynamic response to exercise.      
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Assessment of volume responsiveness using bioreactance and bioimpedance methods    
 
In patients with signs of inadequate tissue perfusion, fluid administration generally is 
regarded as the first step in resuscitation and critical care medicine.(2) Too little fluid may 
result in tissue hypoperfusion and worsen organ dysfunction whereas overprescription of 
fluid can reduce oxygen delivery and compromises patient outcome.(59) Several studies 
suggest that early aggressive resuscitation of critically ill patients may limit or reverse tissue 
hypoxia and progression to organ failure and improve outcome whereas overzealous fluid 
resuscitation has been associated with increased complications, length of intensive care unit 
and hospital stay and mortality.(60-64)  
The primary target of a fluid challenge is to increase stroke volume and to assess volume 
responsiveness. If the fluid challenge does not increase stroke volume, volume loading has no 
useful benefit and may be harmful to the patient.(2, 59) Clinical studies have consistently 
demonstrated that only 50% if hemodynamically unstable patients are volume 
responsive.(65) Therefore it is suggested that the first step in the resuscitation of 
hemodynamically unstable patient is to determine whether the patient is a volume 
responder.(2)  
It has been demonstrated that passive leg raising (PLR) test can predict fluid responsiveness 
as its physiological effects are associated with an increase in venous return and cardiac 
preload.(66) The PLT is therefore an alternative to predict the hemodynamic response to fluid 
administration since it can be used as a “self-volume challenge” at the bedside which is easy 
to perform and completely reversible.(67) Lifting the legs passively from the horizontal plane 
in a lying subject induces a gravitational transfer of blood from the lower part of the body 
toward the central circulatory compartment and especially toward the cardiac cavities.(68) 
Technically, PLR is best performed by both elevating the lower limbs to 45º, while at the 
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same time lowering the patient into the supine position from a 45º semi-recumbent position. 
This technique has recently gained interest as a test for monitoring functional hemodynamic 
and assessing fluid responsiveness since it is a simple way to transiently increase cardiac 
preload from the shift of venous blood from the legs.(69) The physiological response to PLR 
test is similar to that induced by a 200-300 ml fluid bolus.(68) The PLR increases the aortic 
flow time—a marker of left cardiac preload—to the same proportion in both responders and 
nonresponders, suggesting that this test actually performs as a volume challenge.(69) The 
changes in the descending aortic blood observed during a PLR test were closely correlated 
with those induced by the subsequent volume expansion.(67) Moreover, a PLR-induced 
increase in aortic blood flow by more than 10% predicted a fluid-induced increase in aortic 
blood flow by more than 15% (i. e., fluid responsiveness) with very good sensitivity and 
specificity.(66) The PLR is validated independently for its accuracy in assessing fluid 
responsiveness by observing changes in stroke volume.(68)  If the increase in SV is 10% or 
greater from baseline then the patient is fluid responsive, but if it is less than 10% they are 
not fluid responsive.(70) Therefore, the PLR manoeuvre coupled with non-invasive and 
continuous assessment of stroke volume and cardiac output will appear to be ideal method for 
determining volume responsiveness.(59) Indeed, both bioreactance and bioimpedance 
methods have been evaluated for the assessment of volume responsiveness.  
 
Bioreactance evaluation in the assessment of volume responsiveness. Marik and colleagues 
(59) evaluated the accuracy of bioreactance response to PLR test in 34 hemodynamically 
unstable patients and used brachial arterial Doppler ultrasound flow as the reference 
technique. The PLR manoeuvre had a sensitivity of 94% and a specificity of 100% for 
predicting volume responsiveness. Results further revealed that bioreactance stroke volume 
variation was 18% in responders and 15% in nonresponders. There was a strong correlation 
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between the percent change in bioreactance stroke volume index by PLR and the concomitant 
change in carotid blood flow (r=0.59, p=.0003). The authors concluded that a PLR test 
coupled with the bioreactance noninvasive cardiac output monitoring is simple and accurate 
method of assessing volume responsiveness in critically ill patients. In a separate 
investigation, Benomar and associates (71) studied the feasibility of predicting fluid 
responsiveness by PLR using a bioreactance method. In a two centre study design, they 
recruited 75 intensive care unit adult patients immediately after cardiac surgery. Bioreactance 
cardiac output was measured at baseline, during a PLR, and then during a 500 ml fluid 
infusion. The least minimal significant change was 9%. Cardiac output was 4.17±1.04 l/min 
at baseline, 4.38±1.14 L l/min during PLR, 4.16±1.08 l/min upon return to baseline, and 
4.85±1.41 l/min after fluid infusion. The change in cardiac output following fluid bolus was 
highly correlated with the change in cardiac output following PLR (r = 0.77). It was 
concluded that it is clinically valid to use the bioreactance method to predict fluid 
responsiveness from changes in cardiac output during PLR. Additionally, Lee and colleagues 
(72) evaluated bioreactance to monitor changes in stroke volume after administration of fluid 
bolus in pediatric setting in 26 mechanically ventilated children. Results demonstrated that 
bioreactance stroke volume variation predicted fluid responsiveness during mechanical 
ventilation after ventricular septal defect repaint in children. Kupersztych-Hagege and 
colleagues,(53) however, reported that bioreactance cannot accurately estimate cardiac output 
and fluid responsiveness through PLR test in  critically ill patients. However, this study 
design, data analysis and interpretation have been criticized and conclusions opposed by the 
other authors (54, 73) who highlighted several significant deficiencies which include marked 
deviation from appropriate use of bioreactance method, erroneous interpretation of 
referencing citing bioreactance, and lack of adequate data presented to support conclusions. 
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Based on available literature it seems that bioreactance can be used as a clinical tool to 
evaluate volume responsiveness in different clinical settings.  
Most recently, the use of bioreactance in goal directed fluid therapy management has been 
demonstrated. In a prospective study Waldron and colleagues (74) evaluated performance of 
the bioreactance against esophageal doppler monitor to guide the goal-directed fluid therapy 
in one hundred surgery adult patients. Results revealed non-significant difference and good 
agreement between the two methods. Authors concluded that bioreactance can be a viable 
method to guide goal directed fluid therapy.             
 
Bioimpedance evaluation in the assessment of volume responsiveness. In contrast with 
bioreactance, it appears that limited number of clinical studies have tested the accuracy of 
bioimpedance to predict volume responsiveness using PLR.(67)  Fellahi and colleagues (75) 
tested the hypothesis that bioimpedance could be an alternative to pulse contour analysis for 
cardiac index measurement and prediction in fluid responsiveness in 25 intensive care unit 
adult patients following cardiac surgery. The data were collected at baseline, during passive 
leg raising, and after fluid challenge. Bias and limits of agreement were 0.59 l/min and -0.73-
1.62 l/min, with percentage error of 45%. A significant relationship was found between 
bioreactance and pulse contour analysis percent changes after fluid challenge. Areas under 
the receiver operating characteristic curves for changes in cardiac index to predict fluid 
responsiveness were 0.72 for pulse counter analysis and 0.81 for bioimpedance. The authors 
concluded that the two methods can not be used interchangeable but seem consistent to 
monitor cardiac index continuously and could help to predict fluid responsiveness by using 
passive leg raising. Further clinical validation of bioimpedance to predict fluid 
responsiveness it warranted.  
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Assessment of haemodynamic response to physiological stress testing using bioreactance and 
bioimpedance methods 
The cardiopulmonary exercise stress testing has been widely used in clinical cardiology and 
particularly in the management of patients with chronic heart failure. Data obtained from 
cardiopulmonary exercise testing are used to classify severity of disease, evaluate the effect 
of therapy, estimate prognosis, identify mechanisms of exercise intolerance, and develop 
therapeutic interventions.(76) Monitoring cardiac output during stress testing can define 
degree of cardiac dysfunction and has been shown to improve risk stratification, predict 
survival and explain the mechanisms of exercise intolerance in different stages of heart 
failure.(6-8, 57, 58) As the gold standard invasive methods, such as thermodilution and direct 
Fick, are associated with inherent risks and require specialist expertise, both bioreactance and 
bioimpedance methods may have a significant clinical implication in cardiac output 
evaluation under exercise stress testing.     
 
Bioreactance exercise cardiac output. Several studies evaluated bioreactance performance 
under physiological stress testing. The first evaluation of bioreactance under stress testing 
was performed Myers and associates (77) in 23 patients with heart failure. Results 
demonstrated strong relationship between bioreactance cardiac output and peak oxygen 
consumption. In conclusion, the authors suggested that bioreactance cardiac output can 
clinical evaluation of patients with heart failure.  Maurer and colleagues (78) determined the 
feasibility of using bioreactance during exercise testing in a multicentre study using 210 
symptomatic patients with chronic heart failure while measuring gas exchange measures for 
peak oxygen consumption. Results demonstrated a significant correlation between 
bioreactance cardiac output and New York Heart Association functional class, peak oxygen 
consumption and other indices of cardiac and functional performance. In a substudy, the 
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authors also demonstrated good agreement between bioreactance and inert gas rebreathing 
method with mean bias of 0.4 l/min (limits of agreement 1.5-2.3 l/min), and strong coefficient 
of correlation (r=0.8) between the two methods. It was concluded that bioreactance can be a 
useful method for indexing disease severity, prognostication, and for tracking responses to 
treatment in clinical practice and in clinical trials. Rosenblum et al. (79) evaluated the 
hypothesis that bioreactance exercise cardiac output and cardiac power output will add 
significantly to peak oxygen consumption as means of risk-stratifying patients with heart 
failure. They tested 127 patients with reduced ejection fraction using symptom-limited 
exercise testing and in addition to gas exchange variables, measured cardiac output using 
bioreactance. Patients were followed-up on average 404 days to assess endpoints including 
death, heart transplant, or left ventricular assist device implantation. Results indicated that 
among patients with heart failure, peak cardiac power measured with bioreactance and peak 
oxygen consumption has similar association with adverse outcomes and peak power added 
independent prognostic information to peak oxygen consumption in those with advanced 
disease.  
These studies demonstrate capability of bioreactance to evaluate cardiac output under 
cardiopulmonary exercise testing and emphasizes its the importance risk stratification and 
prognosis in heart failure. It should however be noted that no study evaluated accuracy of 
bioreactance against thermodilution under cardiopulmonary exercise testing. Therefore, 
future studies are warranted to validate bioreactance under physiological stress testing.         
 
Bioimpedance exercise cardiac output. An earlier investigation was performed by Thomas 
(80) who evaluated performance of bioimpedance in healthy volunteers and critically ill 
patients. Results revealed that bioimpedance systematically underestimated exercise-induced 
increase in stroke volume and cardiac output.  In a consequent study Thomas and  Crowther 
22 
 
(81) evaluated bioimpedance in 102 consecutive male patients with suspected coronary 
disease prior to cardiac catheterization. In conclusion authors suggested that impedance 
measurements are not a clinically valuable diagnostic tool and that majority of patients with 
abnormal responses could be identified more simply by their poor exercise tolerance or 
abnormal blood pressure response. In contrast, Belardinelly and colleagues (82) examined the 
accuracy and the reproducibility of impedance cardiography in measuring cardiac output and 
stroke volume at rest and during incremental exercise versus thermodilution and direct Fick 
in 25 patients with ischemic cardiomyopathy. Results revealed no significant differences in 
stroke volume and cardiac output between the three methods at any matched work rate. The 
authors concluded that impedance cardiography is accurate and reproducible method of 
measurement of cardiac output and stroke volume over a wide range of workloads. Good 
agreement between bioimpedance and direct Fick methods has also been previously 
demonstrated during maximal exercise testing and its reproducibility confirmed in 20 healthy 
subjects.(83) Charloux and associates (84) evaluated reliability and accuracy of impedance 
cardiography in 40 patients referred to cardiac catheterization under steady state dynamic leg 
exercise. The mean difference in cardiac output between the impedance cardiography and 
direct Fick method and 0.3 l/min during exercise and limits of agreement −2.3-2.9 l/min 
during exercise. The difference between the two methods exceeded 20% in 9.3% of the cases 
during exercise. The authors concluded that impedance cardiography provides a clinically 
acceptable and non-invasive evaluation of cardiac output under exercise condition. Similar 
findings on accuracy and reproducibility of impedance cardiography under exercise testing 
were reported by other investigations in health and disease.(85, 86) A review paper by Yancy 
and colleagues (87) highlighted the use of impedance cardiography in assessment and 
diagnosis, prognosis and treatment of heart failure, however its use during exercise testing 
was not discussed. Kemps and associated (88) evaluated impedance cardiography against 
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direct Fick method under resting and exercise conditions in heart failure and concluded that 
impedance cardiography overestimates cardiac output at rest and during exercise but may still 
be useful method to determine haemodynamic changes in response to exercise.       
In summary, performance of bioimpedance method under exercise testing has been evaluated 
by a large number of investigators over the previous decades. This should not be surprising 
considering that first bioimpedance method was described in 1960s.  Available evidence 
suggests conflicting results on accuracy and reproducibility of bioimpedance when compared 
with a reference method for evaluation of stroke volume and cardiac output. Future 
investigations are warranted to refine bioimpedance method and improve its accuracy for 
evaluating cardiac output under resting and exercise conditions.    
 
Summary 
Bioimpedance and bioreactance methods have been developed for noninvasive continuous 
monitoring of cardiac output in clinical settings. While bioimpedance was developed several 
decades ago, bioreactance is a novel, advanced modification of thoracic bioimpedance 
method for monitoring cardiac output. Bioimpedance uses electric current stimulation for 
identification of impedance variations induced by cyclic changes in blood flow caused by the 
heart beating. Cardiac output is continuously estimated using electrodes and analyzing the 
occurring signal variation with different mathematical models. Despite many adjustments of 
the mathematical algorithms, clinical validation studies of bioimpedance continue to show 
conflicting results. In contrast to bioimpedance which is based on the analysis of 
transthoracic voltage amplitude changes in response to high frequency current, the 
bioreactance technique analyzes the frequency spectra variations of the delivered oscillating 
current. This approach is supposed to result in a higher signal-to-noise ratio and thus in an 
improved performance of the method. In fact, initial validation studies reveal promising 
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results. Both bioimpedance and bioreactance have been evaluated to assess fluid 
responsiveness and cardiac output during stress testing. Direct comparison studies revealed 
that bioimpedance underestimated cardiac output compared to bioreactance. Large 
multicentre validation studies are warranted to establish the validity and reliability of 
bioimpedance and bioreactance methods in challenging clinical settings.       
 
Practice Points  
 Bioimpedance and bioreactance are noninvasive methods for continuous cardiac output 
monitoring, with bioreactance being a novel, refined method for processing the 
impedance signal.   
 In contrast to bioimpedance which is based on the analysis of transthoracic voltage 
amplitude changes in response to high frequency current, the bioreactance technique 
analyzes the frequency spectra variations of the delivered oscillating current. Therefore, 
bioreactance is inherently more robust and has higher signal-to-noise ratio. 
 Bioimpedance might be useful for trend analysis but great care should be taken for 
diagnostic interpretation as the method is associated with several limitations that may 
affect its accuracy.  
 Initial validation studies reveal promising results in regards to bioreactance performance 
in different clinical settings.  
Research Agenda 
 Further refinement of bioimpedance method is necessitated as available validity and 
reliability studies reveal conflicting results. 
 Accuracy of bioimpedance to assess fluid responsiveness requires further investigations. 
 Even several studies reported accuracy of bioreactance method to estimate cardiac output, 
future large multicentre studies are warranted to demonstrate its validity and 
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reproducibility in challenging clinical settings including volume responsiveness 
assessment and central haemodynamic response to physiological and pharmacological 
stimulations.  
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